Charging Into the Minefield of Genes and Racial Difference
By Arthur Allen,
The New York Times
| 05. 15. 2014
Few areas of science have contributed more to human misery than the study of racial difference. In the 1920s, eugenicists from top American universities promoted the sterilization of the unfit and later praised Hitler’s racial codes while advocating laws that would exclude thousands of Jews from our shores.
Contemporary researchers have found it useful to examine genetic variations that affect traits like diabetes in Native Americans or high blood pressure in African-Americans. But in the shadow of the Holocaust, scientists in the United States have largely avoided the classification of races as a “futile exercise,” in the words of the population geneticist Luigi Luca Cavalli-Sforza; the very concept of race is a matter of scientific debate.
In “A Troublesome Inheritance: Genes, Race and Human History,” however, Nicholas Wade argues that scientists need to get over their hang-ups and jump into studies of racial difference. “The intellectual barriers erected many years ago to combat racism now stand in the way of studying the recent evolutionary past,” he writes.
Mr. Wade, a longtime science writer for The New York...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...